ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Property, plant and equipment, net

Astellas Pharma Inc. (4503)

Market cap
¥4.63T
P/E ratio
18.3x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProperty, plant and equipment, net (Million JPY)YoY (%)
Mar 31, 2025328,921+11.98%
Mar 31, 2024293,742+2.54%
Mar 31, 2023286,459+6.47%
Mar 31, 2022269,044+1.67%
Mar 31, 2021264,623-1.48%
Mar 31, 2020268,600+54.83%
Mar 31, 2019173,483+145.51%
Mar 31, 201870,662-2.09%
Mar 31, 201772,170-2.50%
Mar 31, 201674,022-6.46%
Mar 31, 201579,133

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat